Association of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 infection (PASC)
Abstract Background Obstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC).Research Question In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC?Study Design Cross-sectional survey of a general population of 24,803 U.S. adults.Results COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%.Conclusion In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Quan, Stuart F. [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.12.30.23300666 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI042029937 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI042029937 | ||
| 003 | DE-627 | ||
| 005 | 20240424105252.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240101s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.30.23300666 |2 doi | |
| 035 | |a (DE-627)XBI042029937 | ||
| 035 | |a (biorXiv)10.1101/2023.12.30.23300666 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Quan, Stuart F. |e verfasserin |0 (orcid)0000-0002-9474-7679 |4 aut | |
| 245 | 1 | 0 | |a Association of Obstructive Sleep Apnea with Post-Acute Sequelae of SARS-CoV-2 infection (PASC) |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Obstructive sleep apnea (OSA) is associated with COVID-19 infection. Fewer investigations have assessed OSA as a possible risk for the development of Post-Acute Sequelae of SARS-CoV-2 infection (PASC).Research Question In a general population, is OSA associated with increased odds of PASC-related symptoms and with an overall definition of PASC?Study Design Cross-sectional survey of a general population of 24,803 U.S. adults.Results COVID-19 infection occurred in 10,324 (41.6%) participants. Prevalence rates for a wide variety of persistent (> 3 months post infection) putative PASC-related physical and mental health symptoms ranged from 6.5% (peripheral edema) to 19.6% (nervous/anxious). In logistic regression models adjusted for demographic, anthropometric, comorbid medical and socioeconomic factors, OSA was associated with all putative PASC-related symptoms with the highest adjusted odds ratios (aOR) being fever (2.053) and nervous/anxious (1.939) respectively. Elastic net regression identified the 13 of 37 symptoms most strongly associated with COVID-19 infection. Four definitions of PASC were developed using these symptoms either weighted equally or proportionally by their regression coefficients. In all 4 logistic regression models using these definitions, OSA was associated with PASC (range of aORs: 1.934-2.071); this association was mitigated in those with treated OSA. In the best fitting overall model requiring ≥3 symptoms, PASC prevalence was 21.9%.Conclusion In a general population sample, OSA is associated with the development of PASC-related symptoms and a global definition of PASC. A PASC definition requiring the presence of 3 or more symptoms may be useful in identifying cases and for future research. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Weaver, Matthew D. |e verfasserin |0 (orcid)0000-0003-3578-336X |4 aut | |
| 700 | 1 | |a Czeisler, Mark É. |e verfasserin |0 (orcid)0000-0003-3100-7347 |4 aut | |
| 700 | 1 | |a Barger, Laura K. |e verfasserin |0 (orcid)0000-0001-8547-7331 |4 aut | |
| 700 | 1 | |a Booker, Lauren A. |e verfasserin |4 aut | |
| 700 | 1 | |a Howard, Mark E. |e verfasserin |0 (orcid)0000-0001-7262-2632 |4 aut | |
| 700 | 1 | |a Jackson, Melinda L. |e verfasserin |0 (orcid)0000-0003-4976-8101 |4 aut | |
| 700 | 1 | |a Lane, Rashon I. |e verfasserin |0 (orcid)0000-0002-0612-1466 |4 aut | |
| 700 | 1 | |a McDonald, Christine F. |e verfasserin |0 (orcid)0000-0001-6481-3391 |4 aut | |
| 700 | 1 | |a Ridgers, Anna |e verfasserin |0 (orcid)0000-0003-1360-9387 |4 aut | |
| 700 | 1 | |a Robbins, Rebecca |e verfasserin |0 (orcid)0000-0003-0288-2505 |4 aut | |
| 700 | 1 | |a Varma, Prerna |e verfasserin |0 (orcid)0000-0001-5408-1625 |4 aut | |
| 700 | 1 | |a Wiley, Joshua F. |e verfasserin |0 (orcid)0000-0002-0271-6702 |4 aut | |
| 700 | 1 | |a Rajaratnam, Shantha M.W. |e verfasserin |0 (orcid)0000-0001-7527-8558 |4 aut | |
| 700 | 1 | |a Czeisler, Charles A. |e verfasserin |0 (orcid)0000-0002-7408-1849 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.amjmed.2024.02.023 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.30.23300666 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||